These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 26215077)

  • 1. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose conversion between tapentadol immediate and extended release for low back pain.
    Etropolski MS; Okamoto A; Shapiro DY; Rauschkolb C
    Pain Physician; 2010; 13(1):61-70. PubMed ID: 20119464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol. Acute or chronic pain: no therapeutic advance.
    Prescrire Int; 2014 May; 23(149):121-4. PubMed ID: 24926510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol-ER for the treatment of diabetic peripheral neuropathy.
    Games G; Hutchison A
    Consult Pharm; 2013 Oct; 28(10):672-5. PubMed ID: 24129223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tapentadol extended release for chronic pain patients.
    Taylor R; Pergolizzi JV; Raffa RB
    Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
    Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
    Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current considerations for the treatment of severe chronic pain: the potential for tapentadol.
    Pergolizzi J; Alegre C; Blake D; Alén JC; Caporali R; Casser HR; Correa-Illanes G; Fernandes P; Galilea E; Jany R; Jones A; Mejjad O; Morovic-Vergles J; Oteo-Álvaro Á; Radrigán Araya FJ; Simões ME; Uomo G
    Pain Pract; 2012 Apr; 12(4):290-306. PubMed ID: 21797962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic and functional differentiation of tapentadol and tramadol.
    Raffa RB; Buschmann H; Christoph T; Eichenbaum G; Englberger W; Flores CM; Hertrampf T; Kögel B; Schiene K; Straßburger W; Terlinden R; Tzschentke TM
    Expert Opin Pharmacother; 2012 Jul; 13(10):1437-49. PubMed ID: 22698264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T; Schröder W; Tallarida RJ; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2013 Dec; 347(3):794-801. PubMed ID: 24051022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapentadol extended release: in adults with chronic pain.
    Hoy SM
    Drugs; 2012 Feb; 72(3):375-93. PubMed ID: 22316353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.